We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+30.64%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.06B
AUM Growth
+$264M
Cap. Flow
+$103M
Cap. Flow %
9.71%
Top 10 Hldgs %
50.25%
Holding
118
New
40
Increased
18
Reduced
23
Closed
31

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$50.2M
2
NICE icon
Nice
NICE
+$22.7M
3
AMGN icon
Amgen
AMGN
+$18.3M
4
AZN icon
AstraZeneca
AZN
+$16.5M
5
LLY icon
Eli Lilly
LLY
+$13.8M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$22.4M
2
PFE icon
Pfizer
PFE
+$19.7M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$18.3M
4
NVO
Novo Nordisk
NVO
+$11.2M
5
XLP icon
State Street Consumer Staples Select Sector SPDR ETF
XLP
+$7.91M

Sector Composition

Rank Sector Weight
1 Healthcare 64.11%
2 Technology 8.21%
3 Consumer Discretionary 1.63%
4 Industrials 1.41%
5 Communication Services 1.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGNE icon
101
Neurogene
NGNE
$656M
– –
-19,850
Closed -$4.52M
PFE icon
102
Pfizer
PFE
$143B
– –
-579,700
Closed -$19.7M
PRQR icon
103
ProQR Therapeutics
PRQR
$243M
– –
-346,148
Closed -$1.9M
PTGX icon
104
Protagonist Therapeutics
PTGX
$8.79B
– –
-526,075
Closed -$3.71M
FLNA
105
Filana Therapeutics
FLNA
$48.8M
– –
-615,000
Closed -$2.53M
STOK icon
106
Stoke Therapeutics
STOK
$1.8B
– –
-27,254
Closed -$624K
VRTX icon
107
Vertex Pharmaceuticals
VRTX
$121B
– –
-7,000
Closed -$1.67M
XLP icon
108
State Street Consumer Staples Select Sector SPDR ETF
XLP
$14.2B
– –
-145,207
Closed -$7.91M
VIRX
109
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-20,623
Closed -$299K
KA
110
DELISTED
Kineta, Inc. Common Stock
KA
– –
-18,119
Closed -$2.89M
ZYNE
111
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
– –
-100,000
Closed -$383K
APTX
112
DELISTED
Aptinyx Inc. Common Stock
APTX
– –
-411,666
Closed -$889K
GBT
113
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-24,752
Closed -$1.26M
ALNA
114
DELISTED
Allena Pharmaceuticals
ALNA
– –
-667,800
Closed -$643K
ALXN
115
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-249,396
Closed -$22.4M
BMY.RT
116
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
– –
-50,000
Closed -$190K
IMVTU
117
DELISTED
Immunovant, Inc. Units
IMVTU
– –
-94,500
Closed -$1.56M
1 2 3 4
5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2020 Portfolio in Review

As of Q2 2020, Sphera Funds Management held 118 positions worth $1.06B, up 33% from $800M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sphera Funds Management deployed $103M of net new capital in Q2 2020, opening 40 new positions and adding to 18 existing holdings. Its largest new stake was Nice: 129,406 shares worth $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 66% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $18.3M trimmed.

  • Sphera Funds Management's largest Q2 2020 buy was Nice: 129,406 shares worth $24.5M.
  • Sphera Funds Management added most to AbbVie in Q2 2020, an estimated $50.2M increase.
  • Sphera Funds Management's biggest Q2 2020 reduction was Sarepta Therapeutics, cutting an estimated $18.3M.
  • Sphera Funds Management fully exited Alexion Pharmaceuticals in Q2 2020, selling an estimated $22.4M.
  • Sphera Funds Management's ten largest holdings make up 50% of its $1.06B portfolio in Q2 2020.
  • Sphera Funds Management opened 40 new positions and closed 31 in Q2 2020.
  • Sphera Funds Management's portfolio value rose 33% quarter-over-quarter to $1.06B.

Based on Sphera Funds Management's 13F filing for Q2 2020, filed 13 Aug 2020.